| Abstrakt: |
A recent study conducted at Shiraz University of Medical Sciences in Iran has explored the potential of antibody-drug conjugates (ADCs) in cancer therapy. The study focuses on the cell-surface receptor tyrosine kinase c-Met, which is overexpressed in many solid tumors and is therefore a promising target for anticancer treatments. The researchers highlight the potential of ADCs, which combine monoclonal antibodies with small molecules to deliver targeted therapy with minimal damage to normal cells. The study provides an overview of both clinical and preclinical studies on c-Met-targeting ADCs, revealing promising developments in this field. [Extracted from the article] |
